IDDI, Biostatistical and eClinical Services for Clinical Trials

TRIAL DESIGN - RANDOMIZATION - DATA MANAGEMENT - BIOSTATISTICS
Twitter icon
Facebook icon
LinkedIn icon
Google+ icon
YouTube icon
RSS icon

Secondary menu

Home > Resources > [socialmedia:sm Youtube Url]
  • Integrated eClinical Solutions

  • IDDI Trials experience over the last 5 years

  • IDDI Experience in IDMCs over the last 5 years

  • Data Management for Adaptive Monitoring

  • IDDI Experience in Cardiology over the last 5 years

  • IDDI Experience in Ophthalmology over the last 5 years

  • IDDI Experience in Oncology over the last 5 years

  • IDDI Experience in Statistical Analyses of Biomarkers,Gene Signatures and Proteomics

  • Statistical Validation of Biomarkers

  • Scientific Publications

    The broad experience of IDDI is reflected by its publications in medical and statistical journals and by its presence at major conferences.

     

    Read more
  • Success Stories

    Our case studies demonstrate how the methodology and technology of IDDI were key in the conduct of the clinical trials.

    Read more
  • IDDI announces the appointment of Dr .Everardo Saad as Senior Medical Expert

    Louvain-la-Neuve, July 01, 2014 – International Drug Development Institute (IDDI), a  corporation based in Belgium with offices in Boston (MA), Houston (TX) and Cupertino (CA) announces the appointment of Dr. Everardo Saad as Senior Medical Expert as of July 2014. Everardo brings over 12 years of experience in Medical Oncology with a special interest in clinical trial designs for stratified oncology and biomarker-based endpoints for a more efficient development of novel therapies for cancer patients.

    Download
  • IDDI increases audit-readiness and simplifies collaboration by switching to Veeva Systems’ Vault eTMF solution

    IDDI replaced its mix of a paper-based trial master file (TMF) and e-rooms with Veeva Systems’ cloud-based Vault eTMF solution, part of Veeva’s Development Suite. As a CRO that collects, analyses, and reports all data from international phase I through IV clinical trials for sponsors throughout the US, Europe, and Asia, IDDI wanted a single, centralised system to streamline auditing and collaboration.

    Download
  • Testimonials

     

    The testimonials of our customers testify of IDDI's added value of a highly skilled services offering.

     

    Download
  • IDDI reports successful partnership with Ophthotech

    December 5, 2012

    IDDI reports successful partnership with Ophthotech in a Phase IIb study showing superior efficacy of Ophthotech's Novel Anti-PDGF Agent FovistaTM combined with Lucentis® over Lucentis® Monotherapy in Wet AMD.

    Download
  • IDDI reports successful partnership with Oraya Therapeutic

    May 8, 2012

    IDDI reports successful partnership with Oraya Therapeutics for positive INTREPID Study Outcomes With a Non-Invasive Radiation Therapy for Wet AMD

    Download
  • IDDI Reports Partnership with Exonhit

    March 28, 2012

    IDDI (International Drug Development Institute) Reports Partnership with Exonhit for the clinical validation of diagnostic tests. Louvain-la-Neuve, March 28, 2012 – IDDI (International Drug Development Institute), a corporation based in Belgium, announces its collaboration with Exonhit (Alternext: ALEHT), a French biotechnology company focused on personalized medicine and developing targeted therapeutic and diagnostic products in oncology and Alzheimer’s disease.

    Download
  • IDDI-XClinical : The Best of Two Worlds

    March 25, 2011

    The IWR/IVR system ID-net™ developed by IDDI now provides an interface to MARVIN, XClinical's EDC System. 

    Download
  • IDDI reports 18% increase of the group revenues

    IDDI reports 18% increase of the group revenues and 29% increase of sales for year 2010 compared to year 2009. Damien Tremolet, CEO, comments: "Biopharma companies are eagerly needing advanced and innovative statistical designs (such as adaptive or Bayesian designs) that can be presented to regulatory agencies. IDDI is uniquely positioned to provide such high added value expertise combined with unrivalled biostatistical and eClinical services including randomization and Electronic Data Capture."

    Read more
  • IDDI Partners with Helsinn

    January 10, 2011

    IDDI provides randomization, electronic data capture and biostatistical services to Helsinn in two newly initiated studies with palonosetron, a second generation 5-HT3 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) and of post-operative nausea and vomiting (PONV).

    Read more
  • IDDI Partners with Pharmasset

    April 4, 2011

    IDDI provides Randomization & Electronic Data Capture to Pharmasset for its newly initiated phase II trial ATOMIC in Hepatitis C with PSI-7977.

    Read more
  • IDDI Partners with Sanofi Pasteur

    April 10, 2011

    IDDI provides central randomization and vaccine allocation services to Sanofi Pasteur MSD using ID-netTM, in a phase III clinical trial assessing the Immunogenicity and Tolerability of a 9-valent Human Papillomavirus Vaccine in adolescent and preadolescent girls.

    Read more
  • IDDI opens new office in Houston

    April 1, 2011

    IDDI, an eClinical and Biostatistical service provider headquartered in Belgium has opened a new office in Houston, TX on April 1st, 2011.

    Download
  • IDDI Announces Partnership with Medsource

    October 13, 2011

    IDDI partners with Medsource IDDI, a eClinical and Biostatistical service provider since 1991, based in Belgium with offices in Cambridge, MA and Houston, TX, US offering trial design, randomization, data management including EDC and Biostatistical services has teamed with Medsource, another niche Clinical Research Organization on two oncology studies. Medsource headquartered in Houston, TX, focuses on providing high quality clinical monitoring, regulatory and management of complex clinical trials with an expertise in oncology.

    Download
  • IDDI REPORTS PARTNERSHIP WITH OPHTOTECH

    March 25, 2010

    IDDI provides Randomization, Electronic Data Capture and Biostatistical services to Ophthotech in the newly initiated randomized phase II combination study with E10030 in Wet Age-related Macular Degeneration

    Read more
  • IDDI announces Collaborative Agreement with I-Biostat

    June 15, 2010

    IDDI, announces that it has signed a collaborative agreement with I-BioStat, the Interuniversity Institute for Biostatistics and statistical Bioinformatics, which links research and consultancy groups at the Universities of Hasselt and Leuven in Belgium. The agreement will enable IDDI and I-Biostat to offer the full range of biostatistical services to the pharmaceutical and biotechnology sectors.

    Download
  • IDDI reports successful partnership with TiGenix for Approval of ChondroCelect® for cartilage repair

    August 27, 2009

    IDDI's contributed statistical methodology towards approval of ChondroCelect® TiGenix's lead product for the treatment of full thickness cartilage defects in the knee.

    Download
  • IDDI announces nomination of Mr. Damien Tremolet as CEO

    September 30, 2009

    IDDI announces nomination of Mr. Damien Tremolet as CEO as of October 1, 2009. Louvain-la-Neuve, September 30, 2009 IDDI (International Drug Development Institute), a corporation based in Belgium, announces that Mr Damien TREMOLET will become Chief Executive Officer and Member of the Board as of October 1st, 2009. Mr Tremolet has a background in information science and management, and several years of experience in the CRO business, both at IDDI and at ClinPhone and Perceptive Informatics.

    Download